Medicus Pharma Narrows SkinJect Focus To Gorlin Syndrome, Drops Sporadic BCC Program

Medicus Pharma will concentrate SkinJect development on Gorlin syndrome patients with multiple basal cell carcinoma lesions, discontinuing further sporadic BCC development.